Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Japanese Ethical Drug Market Expands by 2.1% in Apr-Jun 2012: IMS Japan
August 27, 2012
- Diovan Approved for Pediatric Hypertension; Japan’s 1st ARB Approved for Pediatric Indication: Novartis
August 27, 2012
- Kyowa Kirin Initiates PII trial of Mogamulizumab in Europe, the US
August 27, 2012
- Once-Daily Administration of Pentasa in Remission Phase Approved; Kyorin Pharmaceutical
August 27, 2012
- Deal with Mylan to Boost Pfizer’s Generic Lineup in Japan with Definite Impact on Competitors
August 27, 2012
- Kyowa Kirin, Otsuka Still Working Out Specifics for Cooperation in Field of Oncology
August 27, 2012
- Forest HD Considering Joint Venture in Indonesia
August 24, 2012
- Pfizer, Mylan Ink Strategic Collaboration in Japan Generics Biz; Aim for No. 3 in Market
August 24, 2012
- Azilva Ranked No. 1 for Third Consecutive Month in Both GP, HP Markets in July: Rep Track Survey
August 23, 2012
- Janssen Pharmaceutical Appoints Goodwin as Next President
August 23, 2012
- Inavir Significantly Prevents Influenza Infection in PIII: Daiichi Sankyo
August 23, 2012
- Eli Lilly Japan Not to File for Listing of Bydureon Due to Expected Rights Return
August 22, 2012
- Shionogi to Launch Quick Flu Diagnostic Kit on September 11
August 22, 2012
- Neoral, Sandimmune Approved for Small Intestine Transplantation: Novartis
August 22, 2012
- Eisai’s Halaven Receives Orphan Drug Designation for Soft-Tissue Sarcoma in US
August 22, 2012
- Pazopanib Approved for aSTS in Europe: GSK
August 22, 2012
- Oncology Japan 2012 to Be Held on November 7, 8
August 22, 2012
- Mediscience Stepping Up Athlete Recruitments as CMRs
August 21, 2012
- ARB Prescription Rate Affected by Doctors’ Evaluations of MRs: M3 Survey
August 21, 2012
- Generic Actos Launched in US; Takeda Grants AG to Teva, Ranbaxy
August 21, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…